U.S. Professional Services Stock News

Jackson Financial Inc. recently completed a US$748.73 million fixed-rate senior unsecured notes offering, issuing 6.150% callable notes due January 15, 2037 at a slight discount to par. At the same time, Jackson’s launch of new registered index-linked annuities with added index options and funding flexibility highlights an effort to broaden and modernize its retirement income lineup. Next, we’ll examine how this combination of new RILA features and fresh long-term funding could shape Jackson...

Encompass Health recently completed a US$500,000,000 private offering of 5.875% senior notes due 2034, primarily to refinance existing 4.500% 2028 notes, repay revolving credit facility borrowings, and cover related fees, while also opening plans for a new 36-bed inpatient rehabilitation hospital in Bridgeport, West Virginia to replace a closed 19-bed unit. This combination of balance sheet reshaping through longer-dated, higher-coupon unsecured debt and continued investment in specialized...

In its latest quarterly update, Fidelity National Financial reported US$3.23 billion in revenue, an 18.2% year-on-year increase that nonetheless fell short of analyst expectations for both sales and earnings per share. This combination of growth and an earnings miss highlighted a gap between the company’s recent operating performance and the projections embedded in prior analyst models. Now we will consider how this revenue and EPS shortfall against expectations affects Fidelity National...

Warby Parker (NYSE:WRBY) has been added to the S&P SmallCap 600 index, a move that can influence its visibility with index funds and institutional investors. The company also announced a partnership with Google to develop AI-powered intelligent eyewear, bringing smart functionality to its consumer eyewear offering. Warby Parker operates across omnichannel retail and e-commerce, selling prescription glasses, sunglasses, contacts and related eye care services. The S&P SmallCap 600 addition...

Over the last 7 days, the United States market has experienced a 2.7% drop, though it has risen by 23% over the past year, with earnings forecasted to grow by 17% annually. In this fluctuating environment, identifying undervalued stocks can present opportunities for investors seeking to capitalize on potential growth and favorable market estimates.

Over the last 7 days, the United States market has dropped 2.7%, yet it has shown resilience with a 23% rise over the past year and expectations for earnings to grow by 17% annually in the coming years. In this context, growth companies with high insider ownership, such as ATRenew and two others we'll explore, can be particularly appealing as they often indicate strong internal confidence in their long-term potential.

Over the last 7 days, the United States market has dropped 2.7%, but it has risen by 23% in the past year, with earnings forecasted to grow by 17% annually. For investors willing to explore beyond well-known stocks, penny stocks—though a somewhat outdated term—still represent an intriguing investment area due to their affordability and potential for growth. This article highlights three penny stocks that stand out for their financial strength and resilience, offering compelling opportunities...

Over the last 7 days, the United States market has experienced a 2.7% drop, yet it remains up by 23% over the past year with earnings forecasted to grow by 17% annually. In such dynamic conditions, dividend stocks that offer consistent payouts and potential for capital appreciation can be an attractive option for investors seeking stability and income.

Apogee Therapeutics (APGE) stock is in focus after positive 16-week Phase 2 APEX data for zumilokibart in atopic dermatitis, followed by a milestone-based, non-dilutive financing package of up to US$1.3b from Blackstone Life Sciences. See our latest analysis for Apogee Therapeutics. After a sharp rally tied to the Phase 2 APEX data and US$1.3b Blackstone financing, Apogee’s share price has eased 4.5% over the last day, although the 1-year total shareholder return of 106.85% points to strong...

In May 2026, Guardian Pharmacy Services, Inc. entered into an eighth amendment to its long-standing loan and security agreement, extending the revolving credit facility’s maturity to May 21, 2030, expanding potential borrowing capacity to US$80 million, and updating covenants to a consolidated net leverage ratio framework. This refinancing package gives Guardian more room to manage debt against cash and Adjusted EBITDA, which may influence how investors assess its balance sheet flexibility...

CPS Technologies (CPSH) has filed a follow-on equity offering to raise US$9.6 million by issuing 1,200,000 common shares at US$8 each in a registered direct deal, introducing fresh capital and potential dilution. See our latest analysis for CPS Technologies. The follow on offering comes after a sharp run, with a 30 day share price return of 95.21% and year to date share price return of 142.19%. The 1 year total shareholder return of 181.82% points to strong longer term momentum despite...

Tarsus Pharmaceuticals (TARS) has been drawing attention after recent trading swings, with the stock closing at US$59.64 while showing mixed returns over the past month and past 3 months, alongside a positive one year track record. See our latest analysis for Tarsus Pharmaceuticals. The share price has been under pressure in recent months, with a 90 day share price return down 18.32% and year to date share price return down 26.16%. At the same time, the 1 year total shareholder return sits at...

Lumentum Holdings recently raised its fourth-quarter guidance and reported very large year-over-year revenue growth, citing intense AI-driven demand for its cloud networking and optical components, while also executing a US$650.4 million private exchange of convertible notes for equity to reduce debt. At the same time, the company secured a multi-year US$2 billion agreement with Nvidia and is expanding manufacturing capacity, including an indium phosphide fab in North Carolina, highlighting...

Event context and recent stock performance Palvella Therapeutics (PVLA) has drawn fresh attention after recent trading saw the stock close at US$105.25. This move comes alongside a year-to-date gain of 5% and a 1-year total return near 3x. See our latest analysis for Palvella Therapeutics. Recent trading has been choppy, with the share price down 3.15% on the day, 6.52% over the past week and 25.94% over the past quarter. At the same time, the 1 year total shareholder return sits near 3x,...

Why Azenta (AZTA) is on investors’ radar today Azenta (AZTA) continues to draw attention after a mixed stretch of performance that includes a gain over the past month but weaker returns year to date and over the past year. With a market value of about US$1.0b and reported revenue of US$596.5m, the company sits in an interesting spot for investors comparing growth potential, profitability and valuation against other life sciences service providers. See our latest analysis for Azenta. At the...

Some Natera, Inc. ( NASDAQ:NTRA ) shareholders may be a little concerned to see that the Lead Independent Director...

Ryder System (R) is back on investors’ radar after a mix of upbeat analyst commentary, positive earnings surprises, and ongoing capital returns, including steady dividends and buybacks, despite a freight market that remains under pressure. See our latest analysis for Ryder System. The recent optimism around Ryder System has coincided with strong momentum, with a 30 day share price return of 13.3% and a 90 day share price return of 33.7%. The 1 year total shareholder return of 80.4% sits...

Cencora recently announced an agreement with Kite, a Gilead Company, to support U.S. distribution of FDA-approved CAR T-cell therapies Yescarta and Tecartus, using its specialty infrastructure to ease access for an expanding network of authorized treatment centers. This move deepens Cencora’s presence in complex cell and gene therapies, highlighting its role in handling highly specialized, patient-specific treatments that can be operationally challenging for providers. Next, we’ll examine...

In early June 2026, NewAmsterdam Pharma filed a US$37.57 million shelf registration for 1,150,000 ordinary shares tied to its ESOP, while shareholders also approved Deloitte Accountants B.V. as external auditor for the 2026 fiscal year and statutory Dutch reporting. Investor attention has been amplified after prominent investor Stanley Druckenmiller highlighted NewAmsterdam Pharma as a top non‑AI idea, coinciding with high-profile healthcare conference appearances to discuss its late-stage...

Recent performance snapshot and context SL Green Realty (SLG) has been drawing attention after a recent stretch of mixed returns, with the stock up over the past week and past 3 months but down over the past year. See our latest analysis for SL Green Realty. For context, the stock’s recent upswing, including a 27.02% 90 day share price return, contrasts with a 20.35% decline in 1 year total shareholder return. As a result, near term momentum appears to be rebuilding from a weaker longer term...

Glacier Bancorp (GBCI) stock has drawn fresh attention after recent trading left it around $47.12, with mixed short term returns that include gains over the past 3 months but a decline over the past month. See our latest analysis for Glacier Bancorp. At around $47.12, the stock’s recent 3 month share price return of 5.39% contrasts with a 3.42% move down over the past month, while the 1 year total shareholder return of 12.90% sits alongside a modest total shareholder loss over 5 years. This...

Victoria's Secret & Co. ( NYSE:VSXY ) just released its latest quarterly results and things are looking bullish. It was...

Recent performance and what has caught investors’ attention Reinsurance Group of America (RGA) has drawn fresh interest after recent share price moves, with the stock ending the latest session at US$201.21 and sitting slightly down year to date. Short term returns have been mixed, with the stock down about 2% over the past week, down roughly 4% over the past month, and lower by around 3% over the past 3 months, while the 1 year total return is slightly positive. See our latest analysis for...

Zevra Therapeutics recently disclosed that shareholders at its June 4, 2026 annual meeting rejected an amendment to phase out the company’s classified board structure, which would have shifted all directors to one-year terms beginning with the 2027 annual meeting. Around the same time, Zevra moved to strengthen its intellectual property position by asking the U.S. Food and Drug Administration to list a new MIPLYFFA patent in the Orange Book, aiming to extend patent protection to 2041 and...